3-(4-ethoxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(4-ethoxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole
• 化学式: C₁₄H₁₆N₂O
• 分子量: 228.29
• InChiKey: BNHBFAPJZHNXTE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer
  申请人：University of Pittsburgh-Of the Commonwealth System of Higher Education

  公开号：US10004730B2

  公开（公告）日：2018-06-26

  A method for treating prostate cancer in a subject, comprising administering a therapeutically effective amount of at least one agent to the subject, wherein the agent is selected from: (a) a phenyl-substituted imidazole, or a pharmaceutically acceptable salt or ester thereof; or (b) a compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of:  wherein R20 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group; R21 is an alkanediyl or a substituted alkanediyl; a is 0 or 1; c is 0 or 1; X is C or S; R22 is a moiety that includes at least one divalent amino radical; and R23 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group.

  一种治疗受试者前列腺癌的方法，包括向受试者施用治疗有效量的至少一种制剂，其中所述制剂选自以下物质 (a) 苯基取代咪唑，或其药学上可接受的盐或酯；或 (b) 具有式 I 的化合物或其药学上可接受的盐或酯： 其中 R20 是芳基、取代的芳基、杂芳基、取代的杂芳基、杂环烷基、取代的杂环烷基、烷氧基、芳氧基、含硅基的基团、含硼酸基的基团、含膦基的基团、氨基、含硫基的基团、含硒基的基团、卤化物或含硝基的基团； R21 是烷二基或取代的烷二基； a 是 0 或 1 c 是 0 或 1； X 是 C 或 S； R22 是包括至少一个二价氨基的分子；和 R23 是芳基、取代的芳基、杂芳基、取代的杂芳基、杂环烷基、取代的杂环烷基、烷氧基、芳氧基、含硅烷基的基团、含硼酸基的基团、含膦基的基团、氨基、含硫代基的基团、含硒代基的基团、卤化物或含硝基的基团。
• SMALL MOLECULES TARGETING ANDROGEN RECEPTOR NUCLEAR LOCALIZATION AND/OR LEVEL IN PROSTATE CANCER
  申请人：University of Pittsburgh - Of the Commonweath System of Higher Education

  公开号：US20140371235A1

  公开（公告）日：2014-12-18

  A method for treating prostate cancer in a subject, comprising administering a therapeutically effective amount of at least one agent to the subject, wherein the agent is selected from: (a) a phenyl-substituted imidazole, or a pharmaceutically acceptable salt or ester thereof; or (b) a compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of: wherein R 20 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group; R 21 is an alkanediyl or a substituted alkanediyl; a is 0 or 1; c is 0 or 1; X is C or S; R 22 is a moiety that includes at least one divalent amino radical; and R 23 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group.
• US9708276B2
  申请人：——

  公开号：US9708276B2

  公开（公告）日：2017-07-18
• US9981974B2
  申请人：——

  公开号：US9981974B2

  公开（公告）日：2018-05-29
• [EN] SMALL MOLECULES TARGETING ANDROGEN RECEPTOR NUCLEAR LOCALIZATION AND/OR LEVEL IN PROSTATE CANCER<br/>[FR] PETITES MOLÉCULES CIBLANT LA LOCALISATION ET/OU LE NIVEAU NUCLÉAIRE DES RÉCEPTEURS DE L'ANDROGÈNE DANS LE CANCER DE LA PROSTATE
  申请人：UNIV PITTSBURG OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

  公开号：WO2013055793A1

  公开（公告）日：2013-04-18

  A method for treating prostate cancer in a subject, comprising administering a therapeutically effective amount of at least one agent to the subject, wherein the agent is selected from: (a) a phenyl-substituted imidazole, or a pharmaceutically acceptable salt or ester thereof; or (b) a compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of: wherein R is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio- containing group, a seleno-containing group, halide, or a nitro-containing group; R 21 is an alkanediyl or a substituted alkanediyl; a is 0 or 1; c is 0 or 1; X is C or S; R 22 is a moiety that includes at least one divalent amino radical; and R 23 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio- containing group, a seleno-containing group, halide, or a nitro-containing group.